Monopar Therapeutics Inc. Common Stock (MNPR)
Monopar Therapeutics Inc. (MNPR) is a biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company aims to advance innovative drug candidates through clinical development with a focus on improving patient outcomes, often emphasizing repurposing existing drugs for new therapeutic applications.
Company News
Monopar Therapeutics is conducting a $135 million underwritten offering of common stock and pre-funded warrants, with plans to use proceeds for general corporate purposes and a stock repurchase from Tactic Pharma.
After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. Peraso posted a quarterly loss of $8.52 per share, versus analysts’ estimates for a loss of $3.76 per share. The company’s quarterly sales came in at $1.83 million versus expectations of $1.7...
Here's why penny stocks climb in value The post What Causes Penny Stocks to Climb in Price? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.